Literature DB >> 2824799

Neuroendocrine and metabolic responses induced by interleukin-1.

H Besedovsky1, A del Rey.   

Abstract

We have previously demonstrated that Interleukin-1 (IL-1), a cytokine mainly produced by activated monocytes, stimulates the pituitary-adrenal axis and affects glucose homeostasis. Comparative studies revealed that a beta form of recombinant human IL-1, similar to the mature peptide secreted naturally, is more powerful than other preparations of this monokine in stimulating adrenocorticotrophic hormone (ACTH) and corticosterone output. Another monokine, tumor necrosis factor (TNF), does not share with IL-1 the capacity to induce such effects. In extending our studies to rats, we showed that increased ACTH and blood corticosterone levels are also induced by IL-1 in this species. Another in vivo activity of IL-1 relates to its capacity to induce a reduction in blood glucose levels. Our studies strongly suggest that, as opposed to other effects elicited by IL-1, blockade of prostaglandin synthesis does not affect the capacity of IL-1 to stimulate insulin output and produce hypoglycemia. Administration of IL-1 to adrenalectomized mice, which are defective in counterregulatory mechanisms of glucose homeostasis, resulted in marked hypoglycemia. In contrast to the response observed in normal mice, in adrenalectomized animals this effect was paralleled by decreased blood insulin levels. IL-1 was also injected into alloxan-diabetic mice. A marked reduction in blood glucose levels occurred in these animals. This effect was already noticeable 1 hr after injection. After 2 hr and for at least another 6 hr, glucose levels of alloxan-treated mice injected with IL-1 remained within the normal range.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824799     DOI: 10.1002/jnr.490180124

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  IL-1 resets glucose homeostasis at central levels.

Authors:  Adriana Del Rey; Eduardo Roggero; Anke Randolf; Carolina Mahuad; Samuel McCann; Valeria Rettori; Hugo O Besedovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-11       Impact factor: 11.205

Review 2.  Lymphocytes as a source of hormones and peptides.

Authors:  A E Panerai
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

Review 3.  Molecular biology of the regulation of hypothalamic hormones.

Authors:  J M Rondeel; I M Jackson
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

4.  Interleukin-1 signaling contributes to acute islet compensation.

Authors:  Catherine Hajmrle; Nancy Smith; Aliya F Spigelman; Xiaoqing Dai; Laura Senior; Austin Bautista; Mourad Ferdaoussi; Patrick E MacDonald
Journal:  JCI Insight       Date:  2016-04-07

5.  Role of IL-1 beta and 5-HT2 receptors in midbrain periaqueductal gray (PAG) in potentiating defensive rage behavior in cat.

Authors:  Suresh Bhatt; Rekha Bhatt; Steven S Zalcman; Allan Siegel
Journal:  Brain Behav Immun       Date:  2007-09-24       Impact factor: 7.217

6.  Brain-borne IL-1 adjusts glucoregulation and provides fuel support to astrocytes and neurons in an autocrine/paracrine manner.

Authors:  A Del Rey; M Verdenhalven; A C Lörwald; C Meyer; M Hernangómez; A Randolf; E Roggero; A M König; J T Heverhagen; C Guaza; H O Besedovsky
Journal:  Mol Psychiatry       Date:  2015-12-08       Impact factor: 15.992

7.  Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity.

Authors:  O Osborn; S E Brownell; M Sanchez-Alavez; D Salomon; H Gram; T Bartfai
Journal:  Cytokine       Date:  2008-08-23       Impact factor: 3.861

8.  Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms.

Authors:  Markus J Schwarz
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

Review 9.  Neuromodulative actions of cytokines.

Authors:  C M Blatteis
Journal:  Yale J Biol Med       Date:  1990 Mar-Apr
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.